ESTIMATED AORTIC PULSE WAVE VELOCITY PREDICTS FUTURE THORACIC AORTIC ANEURYSM EXPANSION: RESULTS FROM A PROSPECTIVE COHORT STUDY WITH SEX-SPECIFIC ANALYSES

2020 ◽  
Vol 36 (10) ◽  
pp. S110-S111
Author(s):  
K. Boczar ◽  
M. Boodhwani ◽  
L. Beauchesne ◽  
C. Dennie ◽  
K. Chan ◽  
...  
Keyword(s):  
Cohort Study ◽  
Aortic Aneurysm ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Thoracic Aortic Aneurysm ◽  
Pulse Wave ◽  
Aortic Pulse Wave Velocity

scholarly journals Coupling between MRI-assessed regional aortic pulse wave velocity and diameters in patients with thoracic aortic aneurysm: a feasibility study

2015 ◽  
Vol 23 (10) ◽  
pp. 493-501 ◽  
Author(s):  
E. S. J. Kröner ◽  
J. J. M. Westenberg ◽  
L. J. M. Kroft ◽  
N. J. Brouwer ◽  
P. J. van den Boogaard ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Feasibility Study ◽  
Thoracic Aortic Aneurysm ◽  
Pulse Wave ◽  
Aortic Pulse Wave Velocity

Role of estimated aortic pulse wave velocity in the prediction of future thoracic aortic aneurysm expansion

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
K Boczar ◽  
M Boodhwani ◽  
L Beauchesne ◽  
C Dennie ◽  
K.L Chan ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
Linear Regression ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Aortic Stiffness ◽  
Thoracic Aortic Aneurysm ◽  
Pulse Wave ◽  
Aortic Pulse Wave Velocity ◽  
Funding Source

Abstract Background Thoracic aortic aneurysm (TAA) is a deadly disease in critical need of novel strategies for risk assessment and medical management. To address this need, we have previously shown that directly measured carotid-femoral pulse wave velocity (cfPWV), a marker of aortic stiffness and health, independently predicts future TAA expansion. Since aortic pulse wave velocity can be estimated from age and mean arterial pressure (MAP), in the present study we sought to determine whether estimated aortic pulse wave velocity (e-aPWV) also predicts TAA expansion. Methods One hundred and five consecutive, unoperated subjects with TAA were recruited. e-aPWV was estimated from validated equations based on age and MAP. cfPWV was measured with arterial tonometry according to guidelines. TAA size was measured at baseline and at the latest follow-up using available imaging modalities according to guidelines. Stepwise multivariable linear regression (P≤0.25 to enter, P≤0.10 to stay in the model) assessed independent associations of e-aPWV and cfPWV with future TAA growth. Variables considered in the models were: age, sex, BSA, MAP, TAA etiology and location, baseline TAA size, follow-up time, imaging modality, history of hypertension, diabetes and smoking. Results Seventy eight percent of subjects were men. Mean±SD age, baseline aneurysm size and follow-up time were 62.6±11.4 years, 46.2±3.8 mm and 3.0±1.0 years, respectively. e-aPWV and cfPWV were moderately correlated (Pearson's correlation coefficient = 0.61). Results of the linear regression analyses showed that both measured (cfPWV) and estimated (e-aPWV) independently predicted future TAA expansion (β±SE: 0.032±0.011, P=0.048 and 0.240±0.085, P=0.006, respectively). The base model's R-squared value of 0.39 was increased to 0.44 with addition of either cfPWV or e-aPWV to the model, confirming that each parameter of aortic stiffness enhances prediction of TAA growth. Conclusion Aortic stiffness is relevant for assessment of TAA disease activity. Similar to cfPWV, e-aPWV is also independently associated with future TAA expansion. Thus, e-aPWV represents a tool to improve TAA risk stratification that is simple, free of cost, and obviates the need for specialized equipment or dedicating training, which leads to excellent potential for widespread incorporation into clinical practice. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): Canadian Institutes of Health Research

scholarly journals Treatment Site Does Not Affect Changes in Pulse Wave Velocity but Treatment Length and Device Selection Are Associated With Increased Pulse Wave Velocity After Thoracic Endovascular Aortic Repair

2021 ◽  
Vol 12 ◽  
Author(s):  
Daijiro Hori ◽  
Tomonari Fujimori ◽  
Sho Kusadokoro ◽  
Takahiro Yamamoto ◽  
Naoyuki Kimura ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
Pulse Wave Velocity ◽  
Endovascular Treatment ◽  
Wave Velocity ◽  
Thoracic Aortic Aneurysm ◽  
Pulse Wave ◽  
Treatment Length ◽  
Treatment Site ◽  
Different Types ◽  
Endovascular Devices

Background: Endovascular treatment of aortic aneurysm is associated with an increase in pulse wave velocity (PWV) after surgery. However, the effect of different types of endovascular devices on PWV at different sites of the thoracic aorta remains unclear.Objectives: The purposes of this study were (1) to investigate the changes in PWV after endovascular treatment of thoracic aortic aneurysm; (2) to evaluate whether there is a difference in the changes in PWV at different treatment sites; and (3) to evaluate the effect of treatment length on changes in PWV.Methods: From July 2008 to July 2021, 276 patients underwent endovascular treatment of the true thoracic aortic aneurysm. Of these patients, 183 patients who underwent preoperative and postoperative PWV measurement within 1 year of surgery were included in the study. The treatment length index was calculated by treatment length divided by the height of the patients.Results: Five different types of endovascular devices were used (Najuta, Kawasumi Laboratories, Inc., Tokyo, Japan; TAG, W.L. Gore & Associates, Inc., AZ, USA; Relay, Bolton Medical, Inc., FL, USA; Talent/Valiant, Medtronic, MN, USA; and Zenith, Cook Medical, IN, USA). There was no significant change in PWV in patients receiving Najuta (Before: 2,040 ± 346.8 cm/s vs. After: 2,084 ± 390.5 cm/s, p = 0.14). However, a significant increase was observed in other devices: TAG (Before: 2,090 ± 485.9 cm/s vs. After: 2,300 ± 512.1 cm/s, p = 0.025), Relay (Before: 2,102 ± 465.3 cm/s vs. After: 2,206 ± 444.4 cm/s, p = 0.004), Valiant (Before: 1,696 ± 330.2 cm/s vs. After: 2,186 ± 378.7 cm/s, p < 0.001), and Zenith (Before: 2,084 ± 431.7 cm/s vs. After: 2,321 ± 500.6 cm/s, p < 0.001). There was a significant increase in PWV in patients treated from aortic arch (Before: 2,006 ± 333.7 cm/s vs. After: 2,132 ± 423.7 cm/s, p < 0.001) and patients treated from descending thoracic aorta (Before: 2,116 ± 460.9 cm/s vs. After: 2,292 ± 460.9 cm/s, p < 0.001). Multivariate analysis showed that treatment site was not an independent factor associated with changes in PWV. However, Najuta (Coef −219.43, 95% CI −322.684 to −116.176, p < 0.001) and treatment index (Coef 147.57, 95% CI 24.826 to 270.312, p = 0.019) were independent factors associated with changes in PWV.Conclusion: Najuta did not show a significant increase in PWV, while other commercially available devices showed a significant increase. The treatment site did not have a different effect on PWV. However, the treatment length was an independent factor associated with an increase in PWV.

Sign in / Sign up

Export Citation Format

Share Document